Postoperative abdominal sepsis induces selective and persistent changes in CTCF binding within the MHC-II region of human monocytes.
Aged
Antigen Presentation
/ physiology
CCCTC-Binding Factor
/ metabolism
Cohort Studies
Female
Genes, MHC Class II
/ physiology
HLA-DR Antigens
/ metabolism
Histocompatibility Antigens Class II
/ metabolism
Humans
Male
Middle Aged
Monocytes
/ metabolism
Nuclear Proteins
/ metabolism
Postoperative Care
/ methods
Sepsis
/ metabolism
Shock, Septic
/ metabolism
Trans-Activators
/ metabolism
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
08
2020
accepted:
14
04
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Postoperative abdominal infections belong to the most common triggers of sepsis and septic shock in intensive care units worldwide. While monocytes play a central role in mediating the initial host response to infections, sepsis-induced immune dysregulation is characterized by a defective antigen presentation to T-cells via loss of Major Histocompatibility Complex Class II DR (HLA-DR) surface expression. Here, we hypothesized a sepsis-induced differential occupancy of the CCCTC-Binding Factor (CTCF), an architectural protein and superordinate regulator of transcription, inside the Major Histocompatibility Complex Class II (MHC-II) region in patients with postoperative sepsis, contributing to an altered monocytic transcriptional response during critical illness. Compared to a matched surgical control cohort, postoperative sepsis was associated with selective and enduring increase in CTCF binding within the MHC-II. In detail, increased CTCF binding was detected at four sites adjacent to classical HLA class II genes coding for proteins expressed on monocyte surface. Gene expression analysis revealed a sepsis-associated decreased transcription of (i) the classical HLA genes HLA-DRA, HLA-DRB1, HLA-DPA1 and HLA-DPB1 and (ii) the gene of the MHC-II master regulator, CIITA (Class II Major Histocompatibility Complex Transactivator). Increased CTCF binding persisted in all sepsis patients, while transcriptional recovery CIITA was exclusively found in long-term survivors. Our experiments demonstrate differential and persisting alterations of CTCF occupancy within the MHC-II, accompanied by selective changes in the expression of spatially related HLA class II genes, indicating an important role of CTCF in modulating the transcriptional response of immunocompromised human monocytes during critical illness.
Sections du résumé
BACKGROUND
Postoperative abdominal infections belong to the most common triggers of sepsis and septic shock in intensive care units worldwide. While monocytes play a central role in mediating the initial host response to infections, sepsis-induced immune dysregulation is characterized by a defective antigen presentation to T-cells via loss of Major Histocompatibility Complex Class II DR (HLA-DR) surface expression. Here, we hypothesized a sepsis-induced differential occupancy of the CCCTC-Binding Factor (CTCF), an architectural protein and superordinate regulator of transcription, inside the Major Histocompatibility Complex Class II (MHC-II) region in patients with postoperative sepsis, contributing to an altered monocytic transcriptional response during critical illness.
RESULTS
Compared to a matched surgical control cohort, postoperative sepsis was associated with selective and enduring increase in CTCF binding within the MHC-II. In detail, increased CTCF binding was detected at four sites adjacent to classical HLA class II genes coding for proteins expressed on monocyte surface. Gene expression analysis revealed a sepsis-associated decreased transcription of (i) the classical HLA genes HLA-DRA, HLA-DRB1, HLA-DPA1 and HLA-DPB1 and (ii) the gene of the MHC-II master regulator, CIITA (Class II Major Histocompatibility Complex Transactivator). Increased CTCF binding persisted in all sepsis patients, while transcriptional recovery CIITA was exclusively found in long-term survivors.
CONCLUSION
Our experiments demonstrate differential and persisting alterations of CTCF occupancy within the MHC-II, accompanied by selective changes in the expression of spatially related HLA class II genes, indicating an important role of CTCF in modulating the transcriptional response of immunocompromised human monocytes during critical illness.
Identifiants
pubmed: 33939725
doi: 10.1371/journal.pone.0250818
pii: PONE-D-20-24667
pmc: PMC8092803
doi:
Substances chimiques
CCCTC-Binding Factor
0
CTCF protein, human
0
HLA-DR Antigens
0
Histocompatibility Antigens Class II
0
MHC class II transactivator protein
0
Nuclear Proteins
0
Trans-Activators
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250818Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Exp Med. 2008 Apr 14;205(4):785-98
pubmed: 18347100
Mol Cell. 2004 Nov 5;16(3):453-63
pubmed: 15525517
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Cell. 2007 May 18;129(4):823-37
pubmed: 17512414
PLoS One. 2015 Mar 20;10(3):e0121748
pubmed: 25793379
Trends Genet. 2001 Sep;17(9):520-7
pubmed: 11525835
Crit Care. 2013 Dec 10;17(6):R287
pubmed: 24321376
Curr Opin Immunol. 2005 Feb;17(1):58-64
pubmed: 15653312
Cell. 2007 Feb 23;128(4):693-705
pubmed: 17320507
Crit Care Med. 2009 May;37(5):1670-7
pubmed: 19325467
J Exp Med. 1995 Feb 1;181(2):765-7
pubmed: 7836928
J Clin Immunol. 1995 Sep;15(5):266-73
pubmed: 8537471
PLoS One. 2018 Sep 13;13(9):e0204168
pubmed: 30212590
Nat Rev Dis Primers. 2016 Jun 30;2:16045
pubmed: 28117397
J Biol Chem. 2006 Jul 7;281(27):18435-43
pubmed: 16675454
Cell. 2009 Jun 26;137(7):1194-211
pubmed: 19563753
J Clin Invest. 1991 Nov;88(5):1747-54
pubmed: 1939659
Crit Care Med. 2010 May;38(5):1276-83
pubmed: 20308885
Cell. 1993 Oct 8;75(1):135-46
pubmed: 8402893
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Am J Respir Crit Care Med. 2004 May 15;169(10):1144-51
pubmed: 15028560
Am J Respir Crit Care Med. 2000 Nov;162(5):1877-83
pubmed: 11069829
Intensive Care Med. 2020 Feb;46(2):163-172
pubmed: 31701205
Cell. 2002 Apr;109 Suppl:S21-33
pubmed: 11983150
Crit Care. 2013 Nov 14;17(6):242
pubmed: 24229432
Intensive Care Med. 2006 Aug;32(8):1175-83
pubmed: 16741700
Br J Cancer. 1997;76(7):836-44
pubmed: 9328140
Intensive Care Med. 2010 Nov;36(11):1859-66
pubmed: 20652682
PLoS One. 2018 Jun 19;13(6):e0198555
pubmed: 29920518
Cell Rep. 2015 Aug 18;12(7):1184-95
pubmed: 26257180
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Blood. 2000 Jul 1;96(1):218-23
pubmed: 10891454
Anaesthesist. 2020 Nov;69(11):826-834
pubmed: 32749501
J Lab Clin Med. 1996 Dec;128(6):594-600
pubmed: 8960643
J Trauma Acute Care Surg. 2012 Jun;72(6):1491-501
pubmed: 22695412
Nature. 1995 Jun 29;375(6534):802-6
pubmed: 7596415
Biochem Biophys Res Commun. 2003 Nov 14;311(2):465-72
pubmed: 14592437
Crit Care Med. 2020 May;48(5):745-756
pubmed: 32167492
Genome Res. 2009 Jan;19(1):24-32
pubmed: 19056695
Mol Cell Biol. 2010 Sep;30(17):4211-23
pubmed: 20584980
Am J Respir Crit Care Med. 2009 Oct 1;180(7):640-8
pubmed: 19590022
Cell. 2008 Jun 13;133(6):1106-17
pubmed: 18555785
Curr Opin Immunol. 2003 Feb;15(1):105-11
pubmed: 12495741
BMC Infect Dis. 2014 Jul 29;14:420
pubmed: 25074742
J Exp Med. 2017 Jul 3;214(7):1913-1923
pubmed: 28606987
Genome Biol. 2017 Apr 27;18(1):76
pubmed: 28449694
J Innate Immun. 2010;2(3):204-15
pubmed: 20375558
J Infect Dis. 1994 Jan;169(1):157-61
pubmed: 8277177
Crit Care. 2011;15(5):R220
pubmed: 21933399
PLoS One. 2014 Apr 14;9(4):e94164
pubmed: 24732314
Clin Epigenetics. 2018 Jun 28;10:89
pubmed: 29988283
Front Immunol. 2013 Dec 20;4:476
pubmed: 24391648
J Hum Genet. 2009 Jan;54(1):15-39
pubmed: 19158813
Crit Care. 2016 Feb 29;20:93
pubmed: 27056672
Scand J Infect Dis. 2011 Dec;43(11-12):883-90
pubmed: 21892899
Chromosoma. 2010 Aug;119(4):351-60
pubmed: 20174815
Nat Med. 1997 Jun;3(6):678-81
pubmed: 9176497